[Ref] Renal Common (1% to 10%): Kidney failure (chronic hemodialysis patients) [Ref] Endocrine Common (1% to 10%): Parathyroid disorder [Ref] Respiratory Very common (10% or more): Pharyngitis (27%), cough increase (18%), dyspnea (11%), rhinitis (11%) Common (1% to 10%): Bronchitis, sinusitis [Ref] Dermatologic Common (1% to 10%): Pruritus, rash [Ref] Ocular Common (1% to 10%): Amblyopia, eye disorder [Ref] Genitourinary Common (1% to 10%): Urinary tract infection [Ref] Cardiovascular Very common (10% or more): Hypertension (21%), hypotension (19%) Common (1% to 10%): Atrial fibrillation, arrhythmia, cardiovascular disorder, electrocardiogram abnormal, palpitations, tachycardia, vascular disorder [Ref] Hypersensitivity Common (1% to 10%): Allergic reaction [Ref] Psychiatric Common (1% to 10%): Depression, anxiety, drug dependence, insomnia [Ref] Immunologic Very common (10% or more): Infection (24%) [Ref] References 1

Tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist used for type 2 diabetes and chronic weight management
There is no functional difference between the two
164 In a randomized crossover trial in 50 subjects with male infertility, one month of treatment with a supplement containing pine bark extract plus L-arginine (an amino acid precursor to nitric oxide which regulates blood vessel function) increased semen volume, sperm number and concentration, motility, and vitality, and improved sperm morphology compared with placebo